Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update
Background: Primary analysis of the phase I/II clinical trial combining pembrolizumab with all-trans retinoic acid (ATRA) for patients with metastatic melanoma showed a median progression-free survival (PFS) of 20.3 months and median overall survival (OS) not reached. Objective: Report 5-year OS and...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251349321 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157552040411136 |
|---|---|
| author | Jessica S. W. Borgers Theresa M. Medina William A. Robinson Kasey L. Couts Elizabeth N. Katsnelson Claire M. Muckle Eduardo Davilla Sapna P. Patel Dexiang Gao Richard P. Tobin Martin D. McCarter |
| author_facet | Jessica S. W. Borgers Theresa M. Medina William A. Robinson Kasey L. Couts Elizabeth N. Katsnelson Claire M. Muckle Eduardo Davilla Sapna P. Patel Dexiang Gao Richard P. Tobin Martin D. McCarter |
| author_sort | Jessica S. W. Borgers |
| collection | DOAJ |
| description | Background: Primary analysis of the phase I/II clinical trial combining pembrolizumab with all-trans retinoic acid (ATRA) for patients with metastatic melanoma showed a median progression-free survival (PFS) of 20.3 months and median overall survival (OS) not reached. Objective: Report 5-year OS and PFS rates. Design: In this single-center, single-arm trial (NCT03200847), 24 anti-PD-1 naïve patients with metastatic melanoma were enrolled between 10/2017 and 07/2020. Methods: The Kaplan–Meier method was used to estimate OS and PFS. Results: At data cutoff (May 14, 2024), all patients had completed treatment, and 58% ( n = 14) remained alive with a median follow-up of 48 months. The updated 5-year OS rate is 54.7% (95% confidence interval (CI): 36.4–82.1), and the 5-year PFS is 36.1% (95% CI: 21.0–62.2), with 33% ( n = 8) having an ongoing complete response. Conclusion: These results underscore the long-term clinical benefit of combining anti-PD-1 with ATRA, with survival rates comparable to anti-PD-1/combinations but with lower toxicity. |
| format | Article |
| id | doaj-art-b8cffe033cb64853a4405dfca1f13a94 |
| institution | OA Journals |
| issn | 1758-8359 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Medical Oncology |
| spelling | doaj-art-b8cffe033cb64853a4405dfca1f13a942025-08-20T02:24:07ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592025-06-011710.1177/17588359251349321Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival updateJessica S. W. BorgersTheresa M. MedinaWilliam A. RobinsonKasey L. CoutsElizabeth N. KatsnelsonClaire M. MuckleEduardo DavillaSapna P. PatelDexiang GaoRichard P. TobinMartin D. McCarterBackground: Primary analysis of the phase I/II clinical trial combining pembrolizumab with all-trans retinoic acid (ATRA) for patients with metastatic melanoma showed a median progression-free survival (PFS) of 20.3 months and median overall survival (OS) not reached. Objective: Report 5-year OS and PFS rates. Design: In this single-center, single-arm trial (NCT03200847), 24 anti-PD-1 naïve patients with metastatic melanoma were enrolled between 10/2017 and 07/2020. Methods: The Kaplan–Meier method was used to estimate OS and PFS. Results: At data cutoff (May 14, 2024), all patients had completed treatment, and 58% ( n = 14) remained alive with a median follow-up of 48 months. The updated 5-year OS rate is 54.7% (95% confidence interval (CI): 36.4–82.1), and the 5-year PFS is 36.1% (95% CI: 21.0–62.2), with 33% ( n = 8) having an ongoing complete response. Conclusion: These results underscore the long-term clinical benefit of combining anti-PD-1 with ATRA, with survival rates comparable to anti-PD-1/combinations but with lower toxicity.https://doi.org/10.1177/17588359251349321 |
| spellingShingle | Jessica S. W. Borgers Theresa M. Medina William A. Robinson Kasey L. Couts Elizabeth N. Katsnelson Claire M. Muckle Eduardo Davilla Sapna P. Patel Dexiang Gao Richard P. Tobin Martin D. McCarter Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update Therapeutic Advances in Medical Oncology |
| title | Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update |
| title_full | Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update |
| title_fullStr | Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update |
| title_full_unstemmed | Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update |
| title_short | Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma: long-term survival update |
| title_sort | pembrolizumab and all trans retinoic acid combination treatment of advanced melanoma long term survival update |
| url | https://doi.org/10.1177/17588359251349321 |
| work_keys_str_mv | AT jessicaswborgers pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT theresammedina pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT williamarobinson pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT kaseylcouts pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT elizabethnkatsnelson pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT clairemmuckle pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT eduardodavilla pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT sapnappatel pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT dexianggao pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT richardptobin pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate AT martindmccarter pembrolizumabandalltransretinoicacidcombinationtreatmentofadvancedmelanomalongtermsurvivalupdate |